Advertisement
Response to Clark and Kupper
Ingo Haase
Department of Dermatology, University of Cologne, Cologne, Germany.
Address correspondence to: Ingo Haase, Department of Dermatology and Center for Molecular Medicine, University of Cologne (CMMC), Joseph-Stelzmann-Strasse 9, 50924 Cologne, Germany. Phone: 49-221-478-86360; Fax: 49-221-478-5949; E-mail: Ingo.Haase@uni-koeln.de.
Find articles by Haase, I. in: JCI | PubMed | Google Scholar
Published December 1, 2006 - More info
J Clin Invest. 2006;116(12):3088–3088. https://doi.org/10.1172/JCI30698.
© 2006 The American Society for Clinical Investigation
Related article:
Abstract
Psoriasis is a chronic inflammatory skin disease unique to humans. In this issue of the JCI, 2 studies of very different mouse models of psoriasis both report that macrophages play a key role in inducing psoriasis-like skin disease. Psoriasis is clearly a polygenic, inherited disease of uncontrolled cutaneous inflammation. The debate that currently rages in the field is whether psoriasis is a disease of autoreactive T cells or whether it reflects an intrinsic defect within the skin — or both. However, these questions have proven difficult to dissect using molecular genetic tools. In the current studies, the authors have used 2 different animal models to address the role of macrophages in disease pathogenesis: Wang et al. use a mouse model in which inflammation is T cell dependent, whereas the model used by Stratis et al. is T cell independent (see the related articles beginning on pages 2105 and 2094, respectively). Strikingly, both groups report an important contribution by macrophages, implying that macrophages can contribute to both epithelial-based and T cell–mediated pathways of inflammation.
Authors
Rachael A. Clark, Thomas S. Kupper
I read with great interest the commentary by Clark and Kupper titled Misbehaving macrophages in the pathogenesis of psoriasis (1) regarding our recently published articles in the JCI (2, 3). I very much appreciate this instructive commentary, but I feel that it should be put in perspective, in particular for readers who are not specialists in the field of psoriasis.
First, to date, only 2 of the 8 mouse models cited in the commentary have shown conclusively that T cells are required in order for the psoriasis-like skin phenotype to develop in the respective model. In these 2 models, elimination of human CD3+ T cells from transplanted skin of 3 psoriatic individuals (4) or depletion of CD4+ T cells from CD18 hypomorphic mice (5) led to an improvement of the phenotype. Three of the other mouse models have shown that injection of in vitro–activated T cells/CD4+ T cells into skin grafts (6, 7) or of MHC-mismatched CD4+ T lymphocytes into SCID mice (8) reproduces or produces a psoriasis-like skin phenotype. This indicates that T cells can be sufficient but does not prove that they are required for the development of the psoriasis-like changes in the skin.
Second, not all psoriasis patients respond sufficiently to cyclosporine A treatment. The amenability of psoriasis to cyclosporine treatment is used as an argument in favor of a pathogenic function of T cells. Although cyclosporine A is one of the most efficient drugs in the treatment of psoriasis, trials and clinical experience indicate that a subset of patients does not sufficiently respond to this treatment. For example, a meta-analysis of 3 controlled studies in 597 patients with severe psoriasis (9) demonstrated that only about half of the patients achieved a 70% or better improvement of their skin symptoms with cyclosporine A. Moreover, cyclosporine A not only affects T cells but also affects many other cell types, e.g., monocytes/macrophages, in which it can inhibit the production of TNF-α (10), a cytokine with a known function in the development of psoriasis.
Third, the T cell–depleting agent denileukin diftitox (ONTAK) has poor efficacy in the treatment of psoriasis. DAB389IL-2 is a fusion protein consisting of IL-2 fused to diphtheria toxin. It binds to cells expressing the high-affinity IL-2 receptor and causes their destruction. In a double-blind, placebo-controlled phase II multicenter trial in patients with psoriasis, the efficacy of DAB389IL-2 as compared with placebo was minimal, and no dose-response relationship could be established (11).
Finally, although it is likely that T lymphocytes have important functions in the development of psoriasis, it seems too early to conclude upon their pathogenic role. While a contribution of T cells may be critical for the development of psoriasis in a number of cases, any generalization of this concept would be premature at present. Instead, it should be considered that pathogenic pathways leading to the multifaceted clinical picture of psoriasis could be heterogeneous and may not necessarily depend on 1 single cell type.
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)